

FAQs about DUVYZAT



Our team at ITF Therapeutics LLC is very pleased to share with you the exciting news that the United States Food and Drug Administration (FDA) has approved DUVYZAT for the treatment of patients 6 years of age and older with Duchenne muscular dystrophy (DMD). We understand that you may have many questions at this time and have prepared the below list of FAQs to provide more details about DUVYZAT. For additional information, please visit [DUVYZAT.com](https://www.duvyzat.com) or speak with your healthcare provider.

1. What is DUVYZAT and what is its regulatory approval status in the US?

DUVYZAT is a prescription medicine for DMD in patients who are 6 years of age and older. It is a histone deacetylase (HDAC) inhibitor. It was approved by the US FDA on March 21, 2024. You can find more information about what DUVYZAT is and how it works in the patient Medication Guide on [DUVYZAT.com](https://www.duvyzat.com).

2. Who is eligible for treatment with DUVYZAT?

DUVYZAT is for patients in the US with DMD who are 6 years of age and older. DMD is a genetic disease, which means that it's caused by changes, or mutations, in genes. DMD may be caused by different types of genetic mutations. Healthcare providers may prescribe DUVYZAT regardless of mutation.

For more information about eligibility for treatment with DUVYZAT, please speak with your healthcare provider.

3. Is it possible for patients to access DUVYZAT now?

Since receiving FDA approval in March, ITF Therapeutics has been working to complete all the necessary steps to make DUVYZAT available to appropriate patients in the US. We announced the commercial launch of DUVYZAT in June 2024. For details, see our press release at [itftherapeutics.com](https://www.itftherapeutics.com).

You can opt in to receive additional updates related to DUVYZAT at [DUVYZAT.com](https://www.duvyzat.com).

4. Will patients receiving DUVYZAT as part of a clinical trial be able to continue to access treatment?

ITF Therapeutics is committed to working with the participants in our clinical trials to ensure they do not experience any lapse in treatment with DUVYZAT. We are coordinating with clinical trial sites to ensure proper support is provided for participants transitioning from the clinical product available in our trials to the commercially available product.

5. What is the distribution plan for DUVYZAT?

DUVYZAT will be distributed by our exclusive specialty pharmacy provider, PantheRx® Rare. PantheRx specializes in supporting patients with rare diseases. Given the rarity of DMD and the complexity of the reimbursement process, we see important advantages for patients, caregivers, and clinicians in working with a single, high-touch specialty pharmacy to case manage this process and meet the needs of the community.



6. Will there be any services in place to support access to DUVYZAT?

As a reflection of our commitment to making treatment with DUVYZAT available to as many appropriate patients in the US as possible, we will provide eligible patients with a comprehensive suite of resources through our patient services program, ITF ARC. This includes support to help patients and families navigate through insurance challenges, personalized pharmacist support, financial assistance for eligible patients, educational materials, and other resources.

For more information about our patient support services, please visit [DUVYZAT.com](https://www.duvyzat.com) or contact ITF ARC at 1-855-4 ITF ARC [1-855-448-3272].

7. Will ITF offer a free drug program for DUVYZAT?

We are committed to making treatment with DUVYZAT available to as many appropriate patients in the US as possible by working with payers to enable access. We also offer a variety of programs to help patients access treatment while insurers complete their assessments. These include:

- A copay assistance program for commercially insured patients, where patients may pay as little as \$0
- A temporary supply program that provides a limited supply of DUVYZAT to help ensure timely start for appropriate patients facing insurance-related delays
- A bridge program for patients currently on therapy who may be changing insurance providers and might otherwise experience a gap in treatment
- A patient assistance program providing DUVYZAT at no charge for eligible patients, based on established criteria

For more information about our patient support services, please visit [DUVYZAT.com](https://www.duvyzat.com) or contact ITF ARC at 1-855-4 ITF ARC [1-855-448-3272].

8. What options are available to patients who are unable to afford DUVYZAT?

We understand that patients may encounter out-of-pocket costs in situations where insurance coverage is insufficient. As a reflection of our commitment to making treatment with DUVYZAT available to as many appropriate patients in the US as possible, we have created a suite of programs to help address potential financial concerns, including:

- A copay assistance program for commercially insured patients, where patients may pay as little as \$0
- A temporary supply program that provides a limited supply of DUVYZAT to help ensure timely start for appropriate patients facing insurance-related delays
- A bridge program for patients currently on therapy who may be changing insurance and might otherwise experience a gap in treatment
- A patient assistance program providing DUVYZAT at no charge for eligible patients, based on established criteria

For more information about our patient support services, please visit [DUVYZAT.com](https://www.duvyzat.com) or contact ITF ARC at 1-855-4 ITF ARC [1-855-448-3272].



9. Will DUVYZAT be available for patients with Becker muscular dystrophy?

DUVYZAT is an HDAC indicated for the treatment of DMD in patients 6 years of age and older. We recognize the significant unmet medical needs of people living with Becker muscular dystrophy (BMD) and their families. Our program for BMD is in the early stages of clinical development.

10. Who is ITF Therapeutics?

ITF Therapeutics is the US-based rare disease division of Italfarmaco S.p.A. Founded in 1938 in Milan, Italy, Italfarmaco is a private global pharmaceutical company that has led the successful development of many innovative therapeutic products approved for use by patients around the world. The company operates in more than 90 countries on 5 continents and continues to advance promising research to address unmet medical needs in a wide range of therapeutic areas.

In January 2024, Italfarmaco launched ITF Therapeutics as a new division in the United States with a focus on the development and commercialization of products to treat rare diseases, including DMD. Building on a legacy grounded in collaboration and innovation, ITF Therapeutics strives to partner with leaders from the US patient advocacy and treatment communities to ensure that our programs reflect and support their unique needs and goals. The establishment of ITF Therapeutics also reflects Italfarmaco's goal to build a world-class team of experts who share a passion to make a positive impact for rare disease communities. For more information about ITF Therapeutics, please visit itftherapeutics.com.

Indication and Important Safety Information

What is DUVYZAT?

DUVYZAT is a prescription medicine that is used for the treatment of Duchenne muscular dystrophy (DMD) in people 6 years of age and older.

It is not known if DUVYZAT is safe and effective in children under 6 years of age.

Important Safety Information

What is the most important information I should know about DUVYZAT?

- **Low platelet counts in your blood (thrombocytopenia).** Platelets are important for blood clotting, and a decrease in their numbers can lead to an increased risk of bleeding or bruising. Your healthcare provider will check your blood count before you start DUVYZAT and regularly during treatment for any signs of thrombocytopenia. Call your healthcare provider right away if you notice any unusual bleeding or small red or purple spots on the skin called petechiae. Your healthcare provider may change your dose of DUVYZAT if your blood platelet counts continue to be low or may stop your treatment with DUVYZAT.
- **Increased levels of fat (triglycerides) in your blood.** You may not have any symptoms, so your healthcare provider will do blood tests before you start DUVYZAT and regularly during treatment to check your triglyceride levels. Your healthcare provider may change your dose of DUVYZAT if your triglyceride levels continue to be high or may stop your treatment with DUVYZAT.

FAQs about DUVYZAT



- **Frequent watery loose stools (diarrhea) and vomiting.** DUVYZAT can cause vomiting and moderate to severe diarrhea. If diarrhea occurs, you should keep track of the frequency and severity of your diarrhea symptoms, drink plenty of fluids, and contact your healthcare provider. Your healthcare provider may change your dose of DUVYZAT if the diarrhea cannot be managed or does not go away. Your healthcare provider may also stop your treatment with DUVYZAT.

Before taking DUVYZAT, tell your healthcare provider about all of your medical conditions, including if you:

- have any heart problems or if you take any medicines that could increase your chance for irregular heart rhythms.
- have any bleeding problems.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Taking DUVYZAT with certain other medicines may affect each other. Taking DUVYZAT with other medicines can cause serious side effects. Do not start or stop other medicines without talking to your healthcare provider.

DUVYZAT can cause serious side effects, including:

- **See “What is the most important information I should know about DUVYZAT?”**
- **changes in the electrical activity of your heart called QT Prolongation.** QT Prolongation can increase the risk of developing a type of irregular heart rhythm known as Torsades de Pointes. Call your healthcare provider right away if you feel faint, have an irregular heartbeat, feel dizzy, or lose consciousness.

The most common side effects of DUVYZAT included diarrhea, nausea, vomiting, stomach pain, low platelet counts in the blood, increased fat level in the blood and fever.

These are not all of the possible side effects of DUVYZAT. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see [full Prescribing Information](#) and [Medication Guide](#).



© 2024 ITF THERAPEUTICS. ALL RIGHTS RESERVED.
DUVYZAT is a registered trademark of Italfarmaco S.p.A.
DUV-US-0004 v2.0 June 2024